Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 314

1.
2.

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.

PMID:
20031900
[PubMed - indexed for MEDLINE]
Free Article
3.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group.

Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.

PMID:
19329177
[PubMed - indexed for MEDLINE]
4.

Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).

Vidt DG, Ridker PM, Monyak JT, Schreiber MJ, Cressman MD.

Clin Ther. 2011 Jun;33(6):717-25. doi: 10.1016/j.clinthera.2011.05.004.

PMID:
21704236
[PubMed - indexed for MEDLINE]
5.

Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

Everett BM, Glynn RJ, MacFadyen JG, Ridker PM.

Circulation. 2010 Jan 5;121(1):143-50. doi: 10.1161/CIRCULATIONAHA.109.874834. Epub 2009 Dec 21.

PMID:
20026779
[PubMed - indexed for MEDLINE]
Free Article
6.

Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.

Carter NJ.

Am J Cardiovasc Drugs. 2010;10(6):383-400. doi: 10.2165/11204600-000000000-00000. Review.

PMID:
21090831
[PubMed - indexed for MEDLINE]
7.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.

PMID:
18997196
[PubMed - indexed for MEDLINE]
Free Article
9.
10.

Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.

Ridker PM, MacFadyen JG, Glynn RJ, Chasman DI.

Circ Cardiovasc Genet. 2011 Jun;4(3):312-7. doi: 10.1161/CIRCGENETICS.110.959353. Epub 2011 Apr 14.

PMID:
21493817
[PubMed - indexed for MEDLINE]
Free Article
11.

Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.

Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group.

Am J Cardiol. 2007 Dec 1;100(11):1659-64. Epub 2007 Oct 24.

PMID:
18036365
[PubMed - indexed for MEDLINE]
12.
13.
14.

Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.

Fonseca FA, Izar MC.

Expert Rev Cardiovasc Ther. 2009 Sep;7(9):1041-56. doi: 10.1586/erc.09.93.

PMID:
19764857
[PubMed - indexed for MEDLINE]
15.

Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

Ridker PM, MacFadyen J, Libby P, Glynn RJ.

Am J Cardiol. 2010 Jul 15;106(2):204-9. doi: 10.1016/j.amjcard.2010.03.018. Epub 2010 Jun 10.

PMID:
20599004
[PubMed - indexed for MEDLINE]
16.

Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.

Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM.

Ann Intern Med. 2010 Apr 20;152(8):488-96, W174. doi: 10.7326/0003-4819-152-8-201004200-00005.

PMID:
20404379
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.

Kones R.

Drug Des Devel Ther. 2010 Dec 9;4:383-413. doi: 10.2147/DDDT.S10812. Review.

PMID:
21267417
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.

Strandberg TE, Feely J, Sigurdsson EL; DISCOVERY study group.

Clin Ther. 2004 Nov;26(11):1821-33.

PMID:
15639694
[PubMed - indexed for MEDLINE]
19.

Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.

Stewart RA.

Future Cardiol. 2009 May;5(3):231-6. doi: 10.2217/fca.09.8.

PMID:
19656039
[PubMed - indexed for MEDLINE]
20.

Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study.

Glynn RJ, MacFadyen JG, Ridker PM.

Clin Chem. 2009 Feb;55(2):305-12. doi: 10.1373/clinchem.2008.120642. Epub 2008 Dec 18.

PMID:
19095726
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk